Going though it now a lot seems like old news.

Going though it now a lot seems like old news.

“Dr. Ndhlovu served on the Company’s Scientific Advisory Board for a period of time. As compensation for that service, Dr. Ndhlovu was granted an option to purchase 50,000 shares of common stock with an exercise price of $3.36 per share that will expire on August 31, 2030, and an option to purchase an additional 50,000 shares of common stock with an exercise price of 0.50 per share that will expire on September 6, 2032. The awards were not subject to disclosure under Regulation S-K Item 404(a), but the Board took them into consideration in determining that Dr. Ndhlovu is independent under the Nasdaq Rules.“


SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth the beneficial ownership of common stock as of May 31, 2023, by (i) beneficial owners of more than 5 percent of our outstanding shares of common stock; (ii) each of our directors; (iii) each of our named executive officers; and (iv) all of our current executive officers and directors as a group.


Amount and Nature of

Percent of

Name and Address of Beneficial Owner (1)

Beneficial Ownership (2)

Total (3)

Beneficial owners of more than 5 percent:




David F. Welch(4)

51,919,899

5.4
%
Current Directors and Executive Officers:




A. Cyrus Arman, Ph.D.(5)

869,564

—
Antonio Migliarese (6)

2,181,226

*
Scott A. Kelly, M.D.(7)

1,116,408

*
Nitya G. Ray, Ph.D.

351,545

*
Karen J. Brunke, Ph.D.(

284,611

*
Ryan C. Dunlap(

185,334

*
Lishomwa C. Ndhlovu, M.D., Ph.D.(

459,611

*
Stephen M. Simes(

178,012

*
Tanya Durkee Urbach(9)

521,724

*
All current directors and executive officers as a group (7 persons)(10)

4,680,082

0.5
%